DIA and the Healthcare Businesswomen’s Association (HBA) today announced a new collaboration to advance the careers of women involved in the regulatory, medical, legal and compliance functions of health care. The associations will embark on a multi-year initiative called the DIA/HBA Leadership Project, which was launched in June at the 2012 DIA Annual Meeting in Philadelphia.
A steering committee of senior women representing pharmaceutical, biotech, and medical device companies will lead this unique initiative.
The steering committee will develop a plan for:
- building a community of like-minded professionals who will share insights into how to nurture and inspire leadership;
- creating and implementing a skill-building road map for success; and
- shaping the direction of women’s initiatives currently underway, or being developed , to support the regulatory, medical, legal and compliance functions.
“Women involved in the regulatory, medical, legal and compliance functions of health care can positively enhance an organization’s reputation, value diversity while stimulating innovation and maximizing the effectiveness of their commercial operations,” asserts Ilyssa Levins, president of the Center for Communication Compliance (CCC). “For this reason, we must accelerate the growth of their leadership skills and increase their impact on the changing business and regulatory environments.” Levins co-chairs the project with DIA President-elect Minnie Baylor-Henry VP of Worldwide Regulatory Affairs at Johnson & Johnson Medical Devices and Diagnostics.
According to Baylor-Henry, “This initiative will build portable and visible skills that go beyond mere technical expertise. It will also establish women in regulatory, medical, legal and compliance as strategic business partners within an organization. Both are practical goals designed to benefit current and future leaders.”
More than 125 women attended the inaugural event to hear a panel of female leaders share their thoughts on the state of women’s leadership today and to learn more about the project’s vision. Panelists included Dr. Freda Lewis-Hall, EVP, chief medical officer at Pfizer and the 2011 HBA Woman of the Year; RADM Sandra Kweder, MD, deputy director of the Office of New Drugs at the Food and Drug Administration (FDA) and DIA board member; and Tracy Rockney, JD, divisional VP of RA at Abbott Pharmaceutical Products Division.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.